종양학 분야 제휴 및 라이선싱 계약(2021-2026년)

Understand the oncology partnering landscape using intelligence from 2,955 real-world collaboration and licensing deals.

Oncology Collaboration and Licensing Deals 2021-2026 provides comprehensive intelligence on 2,955 partnering deals involving oncology assets, technologies and development programs.

Oncology remains one of the most active areas of pharmaceutical and biotechnology partnering, with companies using collaboration and licensing to access novel targets, therapeutic modalities, development programs and commercial opportunities across a rapidly evolving treatment landscape.

The report brings this extensive deal activity together in one resource, enabling users to understand who is partnering, which oncology opportunities are attracting interest, how transactions are structured, what financial terms have been disclosed and how dealmaking differs across therapeutic indications, technologies and stages of development.

Rather than simply providing a list of transactions, the report combines market-wide deal analysis with financial benchmarking, leading dealmaker intelligence, detailed transaction records and access to publicly available contract documents where available.

It provides a practical intelligence and benchmarking resource for business development, licensing, search and evaluation, corporate strategy, R&D strategy, competitive intelligence and legal teams involved in oncology partnering.

Understand the oncology partnering landscape

The report analyzes oncology dealmaking from 2021 to 2026, including:

• Trends in oncology partnering by year
• Deal activity by deal type
• Industry sector
• Stage of development at the time of partnering
• Technology type
• Therapeutic indication
• Most active oncology dealmakers
• Leading deals by disclosed value
• How oncology partnering activity is evolving
• This enables users to identify where activity is concentrated and understand which companies, technologies, development stages and therapeutic areas are attracting partnering interest.
• Benchmark oncology deal financials
• Financial terms in oncology can vary significantly according to the asset, development stage, technology, competitive landscape, rights granted and overall transaction structure.

The report provides dedicated analysis of disclosed financial terms, including:

• Headline deal values
• Upfront payments
• Milestone payments
• Royalty rates
• Users can investigate the individual transactions behind these benchmarks to understand the wider context surrounding the disclosed economics.
• This provides real-world reference points for internal benchmarking, opportunity assessment, deal preparation and negotiation.
• Financial benchmarks are most useful when interpreted alongside the structure and circumstances of comparable transactions rather than as standalone averages, and the report provides the underlying deal intelligence needed to establish that context.
• Identify leading oncology dealmakers and prospective partners
• The report identifies the most active companies in oncology partnering and provides extensive transaction histories that enable users to investigate their previous activity.

This can help users identify:

• Companies actively seeking oncology opportunities
• Prospective licensing and collaboration partners
• Organizations repeatedly partnering in relevant cancer indications
• Companies active at relevant stages of development
• Dealmakers demonstrating interest in particular targets, technologies or therapeutic modalities
• Competitors pursuing related external innovation strategies
• For companies seeking to partner an oncology asset or technology, previous transaction activity can provide valuable evidence of which organizations have demonstrated an appetite for comparable opportunities.
• Compare partnering activity across oncology indications and targets
• Oncology encompasses a very broad range of cancer indications, biological targets and therapeutic approaches, each with different scientific, clinical and commercial dynamics.
• The report analyzes partnering by therapeutic indication and therapeutic target, enabling users to move beyond broad oncology benchmarks and focus on transactions most relevant to a particular program or strategic interest.
• Combined with analysis by technology and development stage, this helps users identify more meaningful comparable transactions and prospective partners.
• Understand how oncology agreements are structured
• The report includes collaboration, licensing, development, research and other partnering transactions.

Depending on the transaction and available disclosure, users can investigate areas including:

• Rights granted and retained
• Research and development responsibilities
• Licensing rights
• Exclusivity
• Geographic rights
• Intellectual property
• Development and regulatory obligations
• Manufacturing and supply responsibilities
• Commercialization rights
• Financial consideration
• Milestones and royalties
• Governance
• Term and termination provisions
• These real-world examples provide useful reference points when considering the appropriate structure for an oncology partnership.
• Learn from real-world contract documents
• Where publicly available, the report provides access to underlying contract documents for selected oncology transactions.

These agreements can provide substantially more detail than headline announcements alone, enabling users to examine how companies have documented areas such as:

• Scope of rights
• Development obligations
• Intellectual property
• Exclusivity
• Financial terms
• Milestone triggers
• Royalty provisions
• Commercialization rights
• Termination and other negotiated provisions
• For teams preparing or negotiating an oncology collaboration or licensing agreement, access to real contract language provides valuable insight into how comparable deals have been structured in practice.
• Comprehensive oncology deal directory
• The report includes a comprehensive directory of 2,955 oncology collaboration and licensing deals, providing an extensive resource for identifying relevant precedent transactions.

Deals can be reviewed by:

• Company
• Technology type
• Therapeutic indication or target
• Contract availability
• Individual transactions are linked to their underlying deal records, providing a route to further deal information and associated contract documentation where available.
• Who should use this report?
• Business Development and Licensing teams
• Identify comparable oncology transactions, prospective partners and relevant deal structures.
• Search and Evaluation teams
• Understand which companies are actively seeking oncology opportunities across relevant indications, technologies, targets and development stages.
• Biotechnology Companies Seeking Partners
• Identify organizations with demonstrated interest in comparable oncology assets and technologies.
• Corporate and R&D Strategy teams
• Understand how competitors and prospective partners are building oncology portfolios through external innovation.
• Competitive and Market Intelligence teams
• Track partnering activity by company, indication, target, development stage and technology to understand evolving strategic priorities.
• Legal and Transaction teams
• Review publicly available contracts and precedent agreement structures to support transaction preparation and negotiation.
• Senior Management and Portfolio Strategy teams
• Understand where capital, partnering attention and external innovation activity are being concentrated across the oncology landscape.
• Turn market-wide oncology intelligence into company-specific insight
• For qualifying customers, Current Partnering can also provide a Customized Executive Partnering Briefing alongside the report.
• The briefing applies the underlying oncology deal intelligence to the customer's own asset, technology, indication, target or partnering objectives.
• Depending on requirements, this can include relevant comparable transactions, prospective partners, competitor activity, development-stage analysis, deal structures, financial benchmarks, royalty analysis, contract insights and other intelligence selected specifically for the client's situation.
• Request a sample or contact Current Partnering to discuss the report and whether a customized analysis can be provided for your organization.

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in oncology dealmaking

• 2.1. Introduction
• 2.2. Oncology partnering over the years
• 2.3. Oncology partnering by deal type
• 2.4. Oncology partnering by industry sector
• 2.5. Oncology partnering by stage of development
• 2.6. Oncology partnering by technology type
• 2.7. Oncology partnering by therapeutic indication

Chapter 3 - Financial deal terms for oncology partnering

• 3.1. Introduction
• 3.2. Disclosed financials terms for oncology partnering
• 3.3. Oncology partnering headline values
• 3.4. Oncology deal upfront payments
• 3.5. Oncology deal milestone payments
• 3.6. Oncology royalty rates

Chapter 4 - Leading oncology deals and dealmakers

• 4.1. Introduction
• 4.2. Most active in oncology partnering
• 4.3. List of most active dealmakers in oncology
• 4.4. Top oncology deals by value

Chapter 5 - Oncology contract document directory

• 5.1. Introduction
• 5.2. Oncology partnering deals where contract document available

Chapter 6 - Oncology dealmaking by therapeutic target

• 6.1. Introduction
• 6.2. Deals by oncology therapeutic target
• Deal directory
• Deal directory - Oncology deals by company A-Z
• Deal directory - Oncology deals by technology type
• Deal type definitions
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Oncology partnering since 2021
• Figure 2: Oncology partnering by deal type since 2021
• Figure 3: Oncology partnering by industry sector since 2021
• Figure 4: Oncology partnering by stage of development since 2021
• Figure 5: Oncology partnering by technology type since 2021
• Figure 6: Oncology partnering by indication since 2021
• Figure 7: Oncology deals with a headline value
• Figure 8: Oncology deals with upfront payment values
• Figure 9: Oncology deals with milestone payment
• Figure 10: Oncology deals with royalty rates
• Figure 11: Active oncology dealmaking activity since 2021
• Figure 12: Top oncology deals by value since 2021